RON Receptor Tyrosine Kinase as a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-Ron ADC Zt/G4-Mmae

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-18-0252
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Autoinhibition of the Ron Receptor Tyrosine Kinase by the Juxtamembrane Domain

Cell Communication and Signaling
BiochemistryCell BiologyMolecular Biology
2014English

Tyrosine Kinase Receptor RON Functions Downstream of the Erythropoietin Receptor to Induce Expansion of Erythroid Progenitors

Blood
BiochemistryImmunologyCell BiologyHematology
2004English

The RON Receptor Tyrosine Kinase Regulates IFN- Production and Responses in Innate Immunity

Journal of Immunology
AllergyImmunology
2008English

Role of Macrophage-Stimulating Protein and Its Receptor, RON Tyrosine Kinase, in Ciliary Motility.

Journal of Clinical Investigation
Medicine
1997English

Pan-Tam Tyrosine Kinase Inhibitor BMS-777607 Enhances Anti-Pd-1 mAb Efficacy in a Murine Model of Triple-Negative Breast Cancer

Cancer Research
Cancer ResearchOncology
2019English

ICAM-1 as a Molecular Target for Triple Negative Breast Cancer

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2014English

Identification of New Candidate Therapeutic Target Genes in Triple-Negative Breast Cancer

Genes and Cancer
Cancer ResearchGenetics
2012English

Estrogen Receptor-Beta Is a Potential Target for Triple Negative Breast Cancer Treatment

Oncotarget
Oncology
2018English

7. PD-L1 in Triple Negative Breast Cancer – Optimal Testing for Therapeutic Efficacy

Pathology
Forensic MedicinePathology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy